期刊文献+

促性腺激素释放激素激动剂及联合激素反加疗法治疗子宫内膜异位症对骨密度1年的影响 被引量:2

A Year effect on bone mineral density in the Treatment of Endometriosis with Gonadotropin Releasing Hormone Agonist Combined with Add back Therapy
下载PDF
导出
摘要 目的 比较促性腺激素释放激素激动剂 (Gn RH- a)联合与不联合激素反加疗法治疗子宫内膜异位症随访 1年对骨密度的影响。方法 将 34例确诊为子宫内膜异位症及子宫肌腺症患者随机分成两组 :A组 17例 ,Goserelin3.6 mg,皮下注射 ,4周 1次 ;B组 17例 ,Goserelin同 A组 +倍美力 0 .3mg (每日口服 1次 ) +安宫黄体酮 5 mg(每日口服 1次 ) ,疗程 12~ 2 4周 ,比较两组治疗后血激素水平及治疗后 2 4周、停药后 6个月、 12个月骨密度变化。结果 两组血雌二醇均降至绝经期水平 ,A组比 B组下降更明显 (P<0 .0 5 )。A组于治疗 2 4周、停药后 6、12个月腰椎骨丢失率分别为 4 .15 %、 3.0 2 %和 1.4 5 % ,股骨颈骨丢失率分别为 2 .93%、 2 .13%和 0 .87% ;B组分别为 2 .39%、 1.75 %、 0 .4 4 %和 1.75 %、 1.12 %、 0 .2 8%。结论  Gn RH- a联合激素反加疗法与 Gn RH- a一样在治疗期间保持低雌激素状态 ,随访 1年 Gn RH- a组骨密度不完全恢复 ,经联合激素反加疗法可使骨密度下降更缓慢 。 Objective\ To evaluate the efficacy and safety of GnRH a alone and in combination with hormone add back therapy in treating endometriosis.Methods\ Thirty two patients with endometriosis were divided into two groups.Group A(17 patients)was treated by goserelin depot 3 6mg subcutaneously every 4 weeks,group B(17 patients)was treated by goserelin depot plus conjugated equine estrogens 0 3mg daily and medroxyprogesterone acetate(MPA)5mg daily for 12 or 24 weeks.Symptoms and signs were recorded before and after the treatment.Serum estradiol was measured by immunoassay before and 12 weeks after treatment and bone density was measured after 12 and 24 weeks.Results Total subjective symptom scores of group A showed 82 6% decrease after 12 weeks and 93 5% after 24 weeks of treatment(P<0 01),while reductions in ovary endometrial cyst were 42% and 71%,respectively(P<0 01) Of group B,there were 79 1% and 93 4% decreases in total subjective symptom scores after 12 and 24 weeks of treatment(P<0 01)with a reduction of 44% and 82% in ovary endometrial cyst,respectively(P<0 01) Suppression of E 2 level in group A was more significantly than in group B(P<0 05) Also hypoestrogenic side effects such as hot flush were more common in group A(87 5%)than in group B(25%).In group A,bone loss rates of lumber and femoral neck were 4 32% and 2 97% respectively 24 weeks later.In group B,they were 2 35% and 1 76%.Conclusions Add back therapy with conjugated equine estrogens and MPA was as effective as GnRH a alone and can alleviate GnRH a induced bone density decrease,hot flush and other side effects.Its suitable for long time therapy. Endometriosis;GnRH a;Add back therapy;Bone mineral density
出处 《福建医药杂志》 CAS 2003年第1期5-7,共3页 Fujian Medical Journal
关键词 子宫内膜异位症 促性腺激素释放激素 反加疗法 骨密度 治疗 Endometriosis GnRHa Addback therapy Bone mineral density
  • 相关文献

参考文献6

  • 1[1]Stevenson JC, Lees B, Gardner R, et al. A comparison of skeletal effects of goserelin and danazol in premenopausal women with endometriosis. Horm Res, 1989, 32 (1 Suppl): 161~165.
  • 2[2]Dodin S, Lemay A, Maheux R, et al. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol, 1991, 77 (Pt 3): 410~415.
  • 3[4]Reichel RP, Schweppe KW. Goserelin (Zoladex) depot in the treatment of endometriosis. Fertil Steril, 1992, 57 (6): 1197~1202.
  • 4[5]Franke HR, Weijer PH, Pennings TM, et al. Gonadotropinreleasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized,placebo-controlled, double-blind trial. Fertil Steril, 2000, 74(30): 534~539.
  • 5[6]Moghissi KS, Schlaff WD, Olive DL, et al. Goserelin acetate(Zoladex) with or without hormone replacement therapy for the treatment of endometriosis Fertil Steril, 1998,69 (6): 1056~ 1062.
  • 6何春妮,宋岩峰,等.长效促性腺激素释放激素激动剂治疗子宫内膜异位症的疗效观察[J].世界医学杂志,2001,5(5):47-48. 被引量:1

同被引文献27

  • 1Crosignani P,Olive D, Bergqvist A, et al . Advances in the management of endometriosis: An update for clinicians[ J ]. Human Reproduction Update, 2006,12(2) : 179 - 189.
  • 2Sharpe KL, Muse KN. Spontaneous and steroid - induced recurrence of endometriosis after suppression by a gonadotropin - releasing hormone agonist in the rat[J]. Am J Obstet Gynecol, 1991,164( 1 Pt 1 ) : 187 - 194.
  • 3Meldrum DR, Chang R J, Lu J, et al. Medical oophorectomy using a long acting GnRH agonist: a possible new approach to the treatment of endometriosis[J]. J Clin Endocrinol Metab, 1982, 54(5) : 1081 - 1083.
  • 4Corm PM, Growley WJ. Gonadotropin releasing hormone and its analogues [J] .N Engl J Med, 1991,324(2): 93- 103.
  • 5Franke HR, Weijer DH, Pennings TM, et al. Gonadotropoin - replacement therapy for treatment of endometriosis: aprospective, randomized, placebo - controlled, double - blind trial [ J ]. Fertil Steril, 2000,74 (3) : 534 - 539.
  • 6Pierce SJ, Gazvani MR, Farguharson RG. Long- term use of gonadotropin- releasong hormone agalogs and hormone replacement therapy in the management of endometriosis : a randomized trial with a 6 - year follow up[J]. Fertil Steril,2000,74(5) : 964 - 968.
  • 7Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with Leuprolide acetate in the treatment of endometriosis - associated pain[ J ]. Fertil steril, 2006, 85 (2) :314 - 325.
  • 8Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus Leuprolide acetate in the treatment of endometriosis-associated pain[J] .Hum Reprod, 2006, 21(1):248-256.
  • 9Zupi E, Marconi D, Sbracia M, et al. Add - back therapy in the treatment of endometriosis- associated pain. Fertile steril[J], 2004, 82(5): 1303- 1308.
  • 10Irahara M, Uemura H, Yasui T, et al. Efficacy of every - other - day administration of conjugated equine estrogen and medroxyprngesterone acetate on gonadotropin - releasing hormone agonists treatment in women with endometriosis[J]. Gvnecol Obstet Invest, 2001, 52(4) :217 - 222.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部